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Abstract
Background: Patients with cancer have an increased risk of VTE. We compared VTE rates and bleeding
complications in 1) cancer patients receiving LMWH or UFH and 2) patients with or without cancer.
Methods: Acutely-ill, non-surgical patients ≥70 years with (n = 274) or without cancer (n = 2,965) received
certoparin 3,000 UaXa o.d. or UFH 5,000 IU t.i.d. for 8-20 days.
Results: 1) Thromboembolic events in cancer patients (proximal DVT, symptomatic non-fatal PE and VTE-related
death) occurred at 4.50% with certoparin and 6.03% with UFH (OR 0.73; 95% CI 0.23-2.39). Major bleeding was
comparable and minor bleedings (0.75 vs. 5.67%) were nominally less frequent. 7.5% of certoparin and 12.8% of
UFH treated patients experienced serious adverse events. 2) Thromboembolic event rates were comparable in
patients with or without cancer (5.29 vs. 4.13%) as were bleeding complications. All cause death was increased in
cancer (OR 2.68; 95%CI 1.22-5.86). 10.2% of patients with and 5.81% of those without cancer experienced serious
adverse events (OR 1.85; 95% CI 1.21-2.81).
Conclusions: Certoparin 3,000 UaXa o.d. and 5,000 IU UFH t.i.d. were equally effective and safe with respect to
bleeding complications in patients with cancer. There were no statistically significant differences in the risk of
thromboembolic events in patients with or without cancer receiving adequate anticoagulation.
Trial Registration: clinicaltrials.gov, NCT00451412
Background
Patients with cancer have a sixfold increased risk of
venous thromboembolism (VTE) compared to those
without [1,2], and active cancer accounts for about 20%
of all new VTE events occurring in the community [3].
The prevention of VTE in patients with cancer is impor-
tant, not only because cancer patients have a particularly
high risk for VTE, but also because treatment of VTE
may be less effective, associated with more bleeding
complications and associated with a significant reduc-
tion in survival [4-9].
Given the known increased risk of VTE in hospitalized
patients with cancer, current guidelines [10-13]
recommend risk-stratified thromboprophylaxis for can-
cer patients at hospital admission with either unfractio-
nated heparins (UFH), low molecular weight heparins
(LMWH) or Fondaparinux. Both the European Society
for Medical Oncology (ESMO) [14] and the Association
of the Scientific Medical Societies (AWMF) in Germany
[11] recommend prophylaxis for hospitalized patients
with cancer. While ESMO equally recommends LMWH,
UFH and Fondaparinux, the German guideline prefers
LMWH over the other options based on extrapolations
from three placebo controlled randomized trials with
LMWH, in which between 5 and 15% of patients had
cancer at baseline [11,15-18]. Beyond these data there
are randomized controlled trials in cancer patients
[19-22] which have demonstrated a prolongation of
overall survival with the addition of LMWH, even in
patients with advanced disease, but neither rates of VTE
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nor bleeding complications differed between groups
[23]. The German guidelines state that additional studies
are needed to resolve this controversy and to clarify
which anticoagulant regimes are most likely to be bene-
ficial [10].
To further explore this issue we did a post-hoc analy-
sis of the CERToparIn For thromboprophYlaxis in medi-
cal patients (CERTIFY) study [24], a trial which
included 3,239 hospitalized medical patients of at least
70 years and an expected significant decrease in mobility
expected for at least 4 days, of which 274 had cancer at
hospital admission. CERTIFY has demonstrated non-
inferiority of the LMWH certoparin 3,000 U anti-Xa o.
d. versus UFH 5,000 IU t.i.d. for the prophylaxis of
venous thromboembolism in acutely ill, non-surgical
patients aged ≥70 years. We aimed to compare VTE risk
and bleeding complications in 1) patients with cancer
receiving either LMWH or UFH and 2) patients with or
without cancer.
Methods
We performed a post-hoc subgroup analysis of CER-
TIFY trial on patients with a diagnosis of co-morbid
cancer. Patients had been randomized to receive either
3,000 U anti Xa OD certoparin (Mono-embolex®,
Novartis Pharma GmbH, Nürnberg, Germany) or 5,000
IU UFH t.i.d. (Liquemin® N 5000, Hoffmann-LaRoche
AG, Grenzach-Wyhlen, Germany) in a double-blind
fashion [24,25]. The protocol was approved by the ethics
committee of Berlin (Landesamt für Gesundheit und
Soziales Berlin) and confirmed by local institutional
review boards as required by local regulations. All
patients provided written informed consent.
Exclusion criteria for CERTIFY were immobilization
longer than three days prior to randomization; immobi-
lization due to cast or fracture; expected major surgical
or invasive procedure within three weeks following ran-
domization; patients with severe sepsis or need for ven-
tilatory support (permitted were continuous positive
airway pressure, oxygen mask etc.); LMWH or UFH
longer than 48 hours in the five days prior to randomi-
zation; indication for anticoagulation or thrombolysis;
life expectancy less than six months or illness with very
high acute mortality (> 30%); acute symptomatic DVT/
PE; acute or history of heparin induced thrombocytope-
nia type II (HIT-II); acute or history of non-hemorrha-
gic stroke (< 3 months); hemorrhagic stroke or
intracranial bleeding (< 12 months); acute or ongoing
intracranial disease; high risk of gastrointestinal bleed-
ing; spinal or epidural anesthesia, lumbar punction
within the last twelve hours; uncontrolled hypertension;
severe liver or renal disease; acute endocarditis; known
active retinopathy, intravitreal or other intraocular
bleeding.
Endpoints
The primary efficacy measure for the present analysis, as
for the overall CERTIFY study, was the combined inci-
dence of proximal DVT, symptomatic non-fatal PE and
VTE related death occurring during the core study (cov-
ering the treatment period of 8-20 days after which
compression ultrasound sonography was performed). All
endpoints were adjudicated by a blinded expert commit-
tee. Secondary efficacy measures included each of the
components of the primary efficacy measure, the inci-
dence of distal DVT (alone and in combination with
proximal DVT), the incidence of symptomatic DVT, the
incidence of a combination of proximal DVT, non-fatal
PE and death from all causes including PE, the inci-
dence of death from all causes; incidence of documented
symptomatic VTE.
Bleeding complications
Major bleeding was defined as fatal bleeding, clinically
overt bleeding associated with a fall of the hemoglobin
concentration greater than 2 g/l compared to the base-
line hemoglobin concentration, clinically overt bleeding
that required transfusion of two or more units of packed
red cells or whole blood, symptomatic bleeding in a cri-
tical area or organ (intracranial, intraspinal, retroperito-
neal, and pericardial). All non-major bleeding
complications were classified as minor bleeding.
Statistical analysis
All patients that received at least one dose of study drug
were included in the safety analysis (safety population).
All patients from the safety population were also
included in the intention to treat (ITT) population. The
number of patients from the ITT population evaluable
for each of the end points is indicated in the respective
figures. Point estimates and respective 95% confidence
intervals (CIs) were calculated. For details of the statisti-
cal analysis of the overall trial see Riess et al. [24]. P-
values were determined from 2-sample t-tests for con-
tinuous- or from asymptotic odds ratio tests (logistic
regression) for binary variables [26]. P-values were
determined from univariate logistic regression or from
the interaction term of a logistic regression model with
factors treatment, subgroup and treatment times sub-
group as appropriate.
Results
VTE and bleeding complications in cancer patients
receiving certoparin or UFH
Cancer patients receiving certoparin (n = 133) and UFH
(n = 141) respectively did not differ substantially in any
of the documented patient characteristics (Table 1).
Thromboembolic event rates in patients receiving cer-
toparin (4.50%) or UFH (6.03%) were not significantly
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different (OR 0.73; 95%CI 0.23-2.39) (Table 2). Event
rates for single thromboembolic endpoints were largely
comparable between both treatment groups, with total
death showing the lowest OR (0.33; 95%CI 0.06-1.64).
Although bleeding complications were not statistically
different between treatment groups (Table 3), there was
a nominal increase in minor bleeding complications in
the UFH group.
Adverse as well as severe adverse events were compar-
able in certoparin vs. the UFH treated patients (59.4 vs.
67.4% for AEs and 7.5 vs. 12.8% for SAEs).
VTE and bleeding complications in patients with or
without cancer
Out of a total of 3,239 patients randomized and treated
in CERTIFY, 274 had cancer and 2,965 patients no signs
of cancer at hospital admission. All were anticoagulated
with either certoparin or UFH. Patients with cancer
were less frequently female (39.1 vs. 61.0%; p < 0.0001),
had a lower body mass index and longer immobilization.
With respect to co-morbidity, patients with cancer had
less cardiac (11.3 vs. 23.2%; p < 0.0001) or respiratory
disorders (8.8 vs. 18.0%; p < 0.0001) (Table 1). For an
Table 1 Baseline demographic characteristics for patients with or without cancer (safety population)









p-value vs. pts with cancer
Female (%) 37.6 40.4 39.1 61.0 < 0.0001^
Mean age (± SD) (y) 79.7 ± 6.4 78.3 ± 5.8 79.0 ± 6.1 78.8 ± 6.3 0.6922~
Mean bodyweight (± SD) (kg) 73.4 ± 14.6 71.2 ± 13.7 72.3 ± 14.2 72.1 ± 15.9 0.8076~
Body Mass Index (± SD) (kg/m2) 25.9 ± 4.5 25.4 ± 4.6 25.6 ± 4.6 26.6 ± 5.4 0.0041~
Reason for hospitalization (%)
Infections and infestations 23.3 28.4 25.9 27.7 0.5210^
Cardiac disorders 14.3 8.5 11.3 23.2 < 0.0001^
Respiratory disease 6.8 10.6 8.8 18.0 < 0.0001^
Neurologic disease 6.8 6.4 6.6 6.6 0.9791^
Gastrointestinal disease 9.0 9.2 9.1 6.3 0.0753^
Vascular disease 3.0 6.4 4.7 5.9 0.4454^
Renal status
GFR ≤ 30 ml/min/1.73 m2 4.6 2.9 3.7 6.1 0.1106*
30 < GFR ≤ 60 ml/min/1.73 m2 52.7 50.0 51.3 52.2
GFR > 60 ml/min/1.73 m2 42.7 47.1 45.0 41.6
Antiplatelet use
Yes 51.1 48.9 50.0 52.2 0.4905^
No 48.9 51.1 50.0 47.8
Hospitalization (mean ± SD) (days) 13.0 ± 8.5 12.6 ± 5.2 12.8 ± 7.0 12.3 ± 6.0 0.2500~
Immobilization (mean ± SD) (days) 10.7 ± 6.3 10.7 ± 4.5 10.7 ± 5.5 9.8 ± 4.2 0.0038~
Mean exposure (± SD) (days) 9.2 ± 3.9 9.1 ± 4.0 9.2 ± 3.9 9.1 ± 3.3 0.6264~
Legend: Pts, patients; SD, standard deviation; UFH, unfractionated heparin; ^ Chi-Square Test; * Chi-Square Test comparing only GFR ≤ 30 ml/min/1.73 m2; ~ t-
Test.
Table 2 Event rates in patients with cancer treated with certoparin or UFH
Pts with cancer at admission Certoparin UFH OR (95%CI) p-value*
n/avail. % n/avail. %
Thromboembolic events
Combined endpoint 5/111 4.50 7/116 6.03 0.73 (0.23-2.39) 0.6078
Proximal DVT 5/111 4.50 5/114 4.39 1.03 (0.29-3.65) 0.9656
Symptomatic non-fatal PE 0/129 0 1/128 0.78 - -
VTE related death 0/131 0 1/132 0.76 - -
Distal DVT 10/101 9.90 7/106 6.60 1.55 (0.57-4.25) 0.3908
Proximal or distal DVT 12/101 11.88 9/106 8.49 1.45 (0.58-3.61) 0.4213
Symptomatic DVT 1/128 0.78 1/125 0.80 0.98 (0.06-15.78) 0.9866
Death from any cause 2/131 1.53 6/132 4.55 0.33 (0.06-1.64) 0.1743
Legend: Pts, patients; UFH, unfractionated heparin; DVT, deep venous thrombosis; PE, pulmonary embolism; OR, odds ratio; CI, confidence interval, * two-sided p-
value for null-hypothesis: difference = 0 or odds ratio = 1.
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overview of cancer types see table 4. A total of 5.5% of
patients were receiving chemotherapy.
Thromboembolic event rates (proximal DVT, sympto-
matic non-fatal PE and VTE related death) were not sig-
nificantly different in patients with cancer versus those
without (5.29 vs. 4.13%; p = 0.4097) (Table 5). While
differences in single thromboembolic endpoints were
only minor, the rate of patients dying from any cause
was increased in patients with cancer (3.04 vs. 1.16%; p
= 0.0136). The rate of major and minor bleeding com-
plications was comparable between both patient groups
(Table 6).
With respect to patient safety, the number of those
experiencing any severity of adverse events was compar-
able (63.5 vs. 61.2%; OR 1.10 (0.85-1.43)), while serious
adverse events and especially death were significantly
more common in those with cancer (Table 7). Differ-
ences between SAE death rates and those of the efficacy
anaylsis are because of a different denominator (inten-
tion to treat vs. safety population).
Discussion
The present subgroup analysis of the CERTIFY trial
resulted in the following findings: 1) Thromboembolic
events were reduced from 6.03 to 4.50% with the use of
certoparin in comparison with UFH, although this did
not reach statistical significance. Further there was a
nominal but not statistically significant increase in
minor bleeding complications as well as all cause death
in the UFH group. 2) The rates of venous thromboem-
bolism in cancer patients are comparable with adequate
anticoagulation (LMWH or UFH) with no difference in
bleeding complications. Serious adverse events and espe-
cially all cause death were however significantly more
common in those with cancer.
VTE and bleeding complications in cancer patients
receiving certoparin or UFH
Both certoparin and UFH were statistically equally effi-
cacious to prevent thromboembolic events in the pre-
sent analysis (6.03% with UFH, 4.50% with certoparin; p
= 0.6078). This is overall in good agreement with the
results of the total CERTIFY trial population in which
event rates were 4.52% with UFH and 3.94% with certo-
parin [24], indicating non-inferiority of certoparin vs.
UFH.
The only comparable analysis was a subanalysis of the
MEDENOX study, in which enoxaparin (20 or 40 mg)
Table 3 Bleeding complications in patients with cancer treated with certoparin or UFH
Pts with cancer at admission Certoparin UFH OR (95%CI) p-value*
n/avail. % n/avail. %
Patients with cancer at admission
with major bleeding 1/133 0.75 1/141 0.71 1.06 (0.07-17.13) 0.9669
with minor bleeding 1/133 0.75 8/141 5.67 0.13 (0.02-1.02) 0.0523
Legend: Pts, patients; SD, UFH, unfractionated heparin; OR, odds ratio; CI, confidence interval, * two-sided p-value for null-hypothesis: difference = 0 or odds ratio
= 1.
Table 4 Cancer types in patients with cancer
Certoparin (n = 133) UFH (n = 141) Total (n = 274)
n % n % n %
Metastases 21 15.8 18 12.8 49 17.9
Blood 17 12.8 24 17.0 41 15.0
Lung/bronchus 11 8.3 26 18.4 37 13.5
Prostate 23 17.3 12 8.5 35 12.8
Colon/rectum 14 10.5 12 8.5 26 9.5
Breast 16 12.0 6 4.3 22 8.0
Pancreas 14 10.5 8 5.7 22 8.0
Skin 10 7.5 8 5.7 18 6.6
Gastrooesophageal 7 5.3 6 4.3 13 4.7
Urogenital 4 3.0 9 6.4 13 4.7
Liver 4 3.0 8 5.7 12 4.4
Kidney 6 4.5 6 4.3 12 4.4
Gynecological 3 2.3 7 5.0 10 3.6
CNS 4 3.0 5 3.5 9 3.3
Others 4 3.0 3 2.1 7 2.6
Unclassified 9 6.8 8 5.7 17 6.2
Legend: * unknown primary tumour.
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was compared to placebo in the prevention of venous
thromboembolism [18]. Venous thromboembolism
(between day 1 and day 14) was defined as deep vein
thrombosis, clinical suspicion of deep vein thrombosis,
(fatal) pulmonary embolism. A total of 18.6% of patients
(22 out of 118 patients with cancer) experienced VTE
during the observation, but no data were presented on
the relative efficacy of enoxaparin vs. placebo in the sub-
group of patients with cancer.
Although bleeding complications were not statistically
different between treatment groups, there was a nominal
decrease in minor (1.50 vs. 6.38%; OR 0.22; 95%CI 0.05-
1.06) bleeding complications in the certoparin group.
This might somewhat relate to the mode of application,
because UFH was administered as a subcutaneous injec-
tion three times daily, while certoparin was administered
once daily. It appears however to translate into a patient
related benefit. Bleeding rates overall were well compar-
able with previous trials [15-18].
VTE and bleeding complications in patients with or
without cancer
Patients with cancer have a sixfold increased risk of
venous thromboembolism (VTE) compared to those
without, but this risk increase has been documented for
patients without prophylaxis [1,2]. The additional risk
can almost be abolished by heparin prophylaxis (UFH or
LMWH) as demonstrated in the present analysis, where
VTE rates (Incidence of proximal DVT, symptomatic
non-fatal PE and death from any cause) were not
increased in patients with cancer versus those without
(5.29 vs. 4.13%; p = 0.4097), reinforcing the need for an
effective prophylaxis. In agreement with data from pre-
vious trials [15-18], the bleeding risk and complications
rates observed were low, justifying the use of pharmaco-
logic thromboprophylaxis in hospitalized patients with
cancer.
Limitations
Despite the high relevance of the present data for
clinical practice, there are some inherent limitations
to the present subgroup analysis. 1) There are consid-
erable differences in VTE risk between patients with
different cancer types and we have not captured these
in sufficient detail to account for differences in
patient characteristics, in particular for the compari-
son of certoparin and UFH. 2) The subgroup of
patients with cancer was small compared to the over-
all sample size of CERTIFY. The power of the analysis
was therefore limited in this subgroup as illustrated
by numerically large differences between the groups
which could not be statistically validated. 3) There is
no possibility to explore the absolute efficacy of either
heparin in comparison to patients receiving no pro-
phylaxis, but there are a number of studies docu-
menting this [15,19-23].
Table 5 Event rates in patients with and without cancer
All patients Pts with cancer at admission Pts without cancer at admission OR (95%CI) p-value*
n/avail. % n/avail. %
Thromboembolic events
Combined endpoint 12/227 5.29 104/2516 4.13 1.29 (0.70-2.39) 0.4097
Proximal DVT 10/225 4.44 98/2516 3.90 1.15 (0.59-2.23) 0.6851
Symptomatic non-fatal PE 1/257 0.39 9/2827 0.32 1.22 (0.15-9.69) 0.8488
VTE related death 1/263 0.38 0/2852 0 - -
Distal DVT 17/207 8.21 178/2270 7.84 1.05 (0.63-1.77) 0.8495
Proximal or distal DVT 21/207 10.14 218/2280 9.56 1.07 (0.67-1.71) 0.7851
Symptomatic DVT 2/253 0.79 7/2814 0.25 3.20 (0.66-15.46) 0.1488
Death from any cause 8/263 3.04 33/2852 1.16 2.68 (1.22-5.86) 0.0136
Legend: Pts, patients; UFH, unfractionated heparin; DVT, deep venous thrombosis; PE, pulmonary embolism; OR, odds ratio; CI, confidence interval, * two-sided p-
value for null-hypothesis: difference = 0 or odds ratio = 1.
Table 6 Bleeding complications in patients with or without cancer (safety population)
All patients Pts with cancer at admission Pts without cancer at admission OR (95%CI) p-value*
n/avail. % n/avail. %
Bleeding complications
with major bleeding 2/274 0.73 15/2965 0.51 1.45 (0.33-6.36) 0.6254
with minor bleeding 9/274 3.28 101/2965 3.41 0.96 (0.48-1.93) 0.9152
Legend: Pts, patients; SD, UFH, unfractionated heparin; OR, odds ratio; CI, confidence interval, * two-sided p-value for null-hypothesis: difference = 0 or odds ratio
= 1.
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Conclusions
Certoparin 3,000 UaXa o.d. and 5,000 IU UFH t.i.d.
were equally effective and safe with respect to bleeding
complications in patients with cancer. There were no
statistically significant differences in the risk of throm-
boembolic events in patients with or without cancer
receiving adequate anticoagulation.
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OR (95%CI) vs. pts. with
cancer
Patients with AEs; n (%) 79 (59.4) 95 (67.4) 0.71 (0.43-1.16) 174 (63.5) 1815 (61.2) 1.10 (0.85-1.43)
Suspected drug relation 5 (3.8) 6 (4.3) 0.88 (0.26-2.95) 11 (4.0) 82 (2.8) 1.47 (0.77-2.79)
Dose adjustment or study drug
interruption
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Study drug discontinuation 6 (4.5) 7 (5.0) 0.90 (0.30-2.76) 13 (4.7) 115 (3.9) 1.23 (0.69-2.22)
Concomitant medication/non- drug
therapy
56 (42.1) 76 (53.9) 0.62 (0.39-1.00) 132 (48.2) 1265 (42.7) 1.25 (0.98-1.60)
Patients with SAEs (n, %) 10 (7.5) 18 (12.8) 0.56 (0.25-1.25) 28 (10.2) 172 (5.8) 1.85 (1.21-2.81)
Deaths from any cause 2 (1.5) 6 (4.3) 0.34 (0.07-1.73) 8 (2.9) 33 (1.1) 2.67 (1.22-5.84)
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Legend: HIT II, Heparin induced thrombocytopenia; UFH, unfractionated heparin; AE, adverse event; SAE, serious adverse event.
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